Prelude Therapeutics Inc
$ 2.24
7.18%
12 Feb - close price
- Market Cap 140,818,000 USD
- Current Price $ 2.24
- High / Low $ 2.30 / 2.01
- Stock P/E N/A
- Book Value 0.77
- EPS -1.47
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.52 %
- ROE -1.04 %
- 52 Week High 4.22
- 52 Week Low 0.61
About
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Analyst Target Price
$4.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-14 | 2025-05-05 | 2025-02-13 | 2024-10-30 | 2024-08-12 | 2024-05-07 | 2024-02-15 | 2023-11-01 | 2023-08-03 | 2023-05-08 | 2023-03-15 |
| Reported EPS | -0.26 | -0.41 | -0.42 | -0.37 | -0.43 | -0.46 | -0.42 | -0.46 | -0.45 | -0.54 | -0.58 | -0.6 |
| Estimated EPS | -0.3697 | -0.48 | -0.48 | -0.4673 | -0.47 | -0.43 | -0.48 | -0.49 | -0.58 | -0.63 | -0.68 | -0.63 |
| Surprise | 0.1097 | 0.07 | 0.06 | 0.0973 | 0.04 | -0.03 | 0.06 | 0.03 | 0.13 | 0.09 | 0.1 | 0.03 |
| Surprise Percentage | 29.6727% | 14.5833% | 12.5% | 20.8217% | 8.5106% | -6.9767% | 12.5% | 6.1224% | 22.4138% | 14.2857% | 14.7059% | 4.7619% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PRLD
2026-02-08 21:11:04
Prelude Therapeutics Inc. has received FDA clearance for its investigational drug, PRT12396, to begin human trials, signaling a critical validation for its partnership with Incyte. The Phase 1 clinical study for PRT12396, a selective inhibitor targeting the JAK2V617F mutation, is slated for Q2 2026, with the potential for milestone payments up to $910 million from the Incyte collaboration. This regulatory milestone has positively impacted Prelude's stock performance, with shares stabilizing above the $2.00 mark.
2026-02-04 10:59:06
Citizens has reiterated a Market Outperform rating for Prelude Therapeutics (NASDAQ:PRLD) with a $3.00 price target, citing an anticipated 31% upside. The firm highlighted the IND clearance for PRT12396 as a key milestone and noted the company's strong capital position and narrowed pipeline focus. Initial clinical readouts for PRT12396 are expected in the first half of 2027, potentially earlier.
2026-02-03 17:28:35
Prelude Therapeutics received FDA approval to start a Phase 1 trial for PRT12396, a blood cancer treatment developed with Incyte, targeting myeloproliferative neoplasms. This positive development comes despite Prelude Therapeutics facing significant financial challenges, as indicated by negative margins, ongoing losses, and an Altman Z-Score in the distress zone. While the FDA approval is positive, the company's financial health and sector-specific risks warrant investor caution.
2026-02-03 16:59:14
Prelude Therapeutics Inc. (NASDAQ:PRLD) saw its stock jump 7.9% after the FDA cleared its Investigational New Drug (IND) application for PRT12396, a mutant-selective JAK2V617F inhibitor designed to treat myeloproliferative neoplasms (MPNs). The company plans to begin dosing the first patient in a Phase 1 study by the second quarter of 2026, marking a significant step in its strategic focus on oncology programs. This drug program is also subject to an exclusive option agreement with Incyte.
2026-02-03 16:28:35
Prelude Therapeutics Inc. (NASDAQ:PRLD) stock surged after the FDA cleared its Investigational New Drug (IND) application for PRT12396, a cancer drug targeting myeloproliferative neoplasms (MPNs). The company plans to begin the Phase 1 study, evaluating safety, efficacy, and pharmacokinetics, by the second quarter of 2026. This clearance is a significant milestone in Prelude's strategic shift to focus on its JAK2 and KAT6 oncology programs.
2026-02-03 15:28:35
The FDA has cleared Prelude Therapeutics' Investigational New Drug (IND) application for PRT12396, a mutant-selective JAK2V617F inhibitor. This clearance allows Prelude Therapeutics to begin clinical trials for PRT12396, which is designed to treat specific hematologic malignancies by targeting the JAK2V617F mutation. The company plans to assess the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy in human patients.
